- Neko Health closed a $700M Series C led by Lightspeed and O.G. Venture Partners, valuing the company at nearly $7 billion — roughly 4x its $1.7B Series B just 18 months earlier.
- The cap table reads like a tech-and-culture summit: Mark Zuckerberg and Priscilla Chan, OpenAI, Tim Ferriss, will.i.am, and Maria Sharapova all joined the round.
- Neko’s real moat is full vertical integration — it designs, patents, and manufactures its own scanners, software, and clinical protocols entirely in-house.
- With 100,000+ scans completed, a 350,000-person waitlist, and 75% of members pre-paying for next year, Neko opens its first U.S. clinic in Manhattan later this year.
Spotify built its fortune predicting what you want to hear next. Its founder’s second act is far more ambitious: predicting what your body is about to do. Neko Health, the body-scanning startup co-founded by Daniel Ek, just raised a $700 million Series C at a valuation approaching $7 billion — one of the largest health-tech rounds of 2026 and a signal that “preventive medicine” has become a venture category of its own.
The Deal: $700M and a Near-$7B Valuation
A fourfold markup in 18 months
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD. It follows Neko’s $260 million Series B in January 2025, which valued the Swedish-born company at $1.7 billion. Reaching nearly $7 billion so quickly is a rare pace of markup in a market that has otherwise grown cautious about consumer health hardware.
Why the celebrity cap table matters
Beyond the institutional funds, Neko attracted an unusual roster of individual backers: Mark Zuckerberg and Priscilla Chan, OpenAI, author-investor Tim Ferriss, will.i.am, and tennis star Maria Sharapova. For a physical-clinic business, that mix functions as a distribution asset — each name carries reach into a demographic Neko needs, from Silicon Valley operators to wellness-focused consumers.
Business Insight — A near-$7B valuation on a business with a few dozen physical rooms is not a bet on today’s revenue. Investors are pricing Neko as a data company that happens to own clinics — the scans are the customer-acquisition engine, and the longitudinal health dataset is the asset that compounds.
Why It’s Really an AI Business
Vertical integration as the moat
Unlike marketplace or software-only health startups, Neko rejects third-party medical-equipment vendors entirely. It designs, patents, and manufactures its imaging hardware, cloud software, and clinical protocols in-house. That control lets it ship new diagnostic capabilities months faster than competitors bound to external supply chains — last month it launched a new generation of devices it calls Derma-2, Echo-2, and Spectrum-2.
The 60-minute data pipeline
A single visit is a highly orchestrated, roughly 60-minute pipeline. Thousands of proprietary sensors in a non-invasive, radiation-free room capture millions of baseline data points on skin, cardiovascular, and circulatory health. On-site bloodwork adds metabolic and pre-diabetes biomarkers within the same appointment, and a native app links to Apple Health to fold in sleep, heart-rate variability, and activity. The output is a high-definition “map of your biology” reviewed with a clinician — and, crucially, a structured dataset that improves the model with every scan.
Business Insight — The vertical stack is what turns Neko into an AI flywheel. Owning the hardware means owning the data format; owning the data means every new clinic makes the diagnostic models sharper. Rivals licensing off-the-shelf scanners can copy the room but not the compounding dataset.
The Numbers Investors Are Betting On
Demand and retention that look like software
More than 100,000 members across the U.K. and Sweden have completed a Neko scan, and the waitlist exceeds 350,000. The retention metric is what stands out: 75% of members book and pre-pay for their next annual scan before leaving their first appointment. For a physical-clinic model, that is subscription-grade loyalty — and it de-risks the capital cost of each new location.
Early evidence of clinical payoff
Neko says three in four members who had a severe or life-threatening anomaly flagged now have it under control or are in good health, and it reports statistically significant improvement across five of seven core biomarkers between a first and second scan. Anecdotes help too: Calm founder Alex Tew publicly credited a Neko scan with catching a malignant mole. If those outcomes hold at U.S. scale, Neko can pitch employers and insurers — not just consumers.
Business Insight — Prepaid annual scans plus demonstrable outcomes are the two things a preventive-health company needs to escape the “worried wealthy” niche. The waitlist proves demand; the biomarker data is the wedge into enterprise and payer contracts, where the real revenue lives.
The Race to Own Prevention
A new competitive front opens
Neko is not alone in betting that scanning becomes a consumer ritual. Midjourney — better known for AI image generation — is building its own body scanner, which it plans to fold into a spa experience with hot tubs and saunas in San Francisco in 2027. The strategic question is whether preventive scanning becomes a medical category or a lifestyle one. Neko is planting its flag firmly on the clinical side, opening its first U.S. clinic in Manhattan later this year against a broader digital-health funding rebound.
Business Insight — The U.S. market is the real test. American regulation, liability, and reimbursement are far messier than Europe’s, and consumer trust in a body-scan-plus-data model is unproven at scale. The $700M is less about building clinics and more about buying time to prove the model works in the hardest market first.
Related
- Neko’s $260M Series B: How the body-scanning bet began
- Rock Health H1 2026: Digital-health startups hit $7.4B in a venture rebound
- Midjourney’s body scanner: AI image lab moves into medical hardware
- Satya Nadella’s warning to companies rushing into AI
- More biotech and health startup coverage
Sources
- TechCrunch — Daniel Ek’s body-scanning startup Neko Health raises another $700M
- HIT Consultant — Neko Health Secures $700M to Fund U.S. Preventive Clinic Expansion
AI Biz Insider · AI Business EN · aibizinsider.com
댓글 남기기